Literature DB >> 21888603

Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009.

Yu-Tao Xiang1, Chuan-Yue Wang, Tian-Mei Si, Edwin H M Lee, Yan-Ling He, Gabor S Ungvari, Helen F K Chiu, Naotaka Shinfuku, Shu-Yu Yang, Mian-Yoon Chong, Ee-Heok Kua, Senta Fujii, Kang Sim, Michael K H Yong, Jitendra K Trivedi, Eun-Kee Chung, Pichet Udomratn, Kok-Yoon Chee, Norman Sartorius, Lisa B Dixon, Julie A Kreyenbuhl, Chay-Hoon Tan.   

Abstract

OBJECTIVE: Optimizing treatment and outcomes for people with schizophrenia requires understanding of how evidence-based treatments are utilized. Clozapine is the most effective antipsychotic drug for treatment-refractory schizophrenia, but few studies have investigated trends and patterns of its use over time internationally. This study examined the prescription patterns of clozapine and its demographic and clinical correlates in Asia from 2001 to 2009.
METHOD: Clozapine prescriptions were collected in a sample of 6761 hospitalized schizophrenia patients in nine Asian countries and regions using a standardized protocol and data collection procedure.
RESULTS: Overall, the proportion of patients receiving clozapine prescriptions was stable across the three surveys from 2001 to 2009, ranging from 14.5% to 15.9%. However, the rates and patterns observed within different regions and countries at each survey differed considerably. Clozapine use decreased significantly over time in China, while it increased in Korea and Singapore. Multiple logistic regression analysis revealed that patients taking clozapine were significantly younger, had a higher dose of antipsychotic drugs in chlorpromazine equivalents, were more likely to be female, had fewer extrapyramidal symptoms, and had more negative symptoms, admissions and weight gain in the past month than those not receiving clozapine.
CONCLUSION: The variability in overall rates and changes in prescription rates over time in these samples suggest that factors other than psychopharmacological principles play an important role in determining the use of clozapine in schizophrenia in Asia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888603     DOI: 10.3109/00048674.2011.607426

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  12 in total

Review 1.  A bibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore.

Authors:  Francisco López-Muñoz; Kang Sim; Winston Wu Shen; Lorena Huelves; Raquel Moreno; Juan de Dios Molina; Gabriel Rubio; Concha Noriega; Miguel Ángel Pérez-Nieto; Cecilio Alamo
Journal:  Singapore Med J       Date:  2014-01       Impact factor: 1.858

Review 2.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

3.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

4.  Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies.

Authors:  Tian-Mei Si; Yun-Shu Zhang; Liang Shu; Ke-Qing Li; Xie-He Liu; Qi-Yi Mei; Gao-Hua Wang; Pei-Shen Bai; Li-Ping Ji; Xian-Sheng Cheng; Cui Ma; Jian-Guo Shi; Hong-Yan Zhang; Hong Ma; Xin Yu
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

5.  Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.

Authors:  Seon-Cheol Park; Myung-Soo Lee; Seung-Gul Kang; Seung-Hwan Lee
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

6.  Current status of clozapine in the United States.

Authors:  Deanna L Kelly; Heidi J Wehring; Gopal Vyas
Journal:  Shanghai Arch Psychiatry       Date:  2012-04

Review 7.  Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement.

Authors:  Nilamadhab Kar; Socorro Barreto; Rahul Chandavarkar
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

8.  Changing trends in anti-psychotic prescription pattern in Pakistan.

Authors:  Mazhar Malik; M Usman Ghani; Wardha Mazhar; Nargis Munir
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

9.  Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.

Authors:  Deanna L Kelly; Raymond C Love
Journal:  Ment Health Clin       Date:  2019-03-01

10.  Trends in scientific literature on atypical antipsychotics in South Korea: a bibliometric study.

Authors:  Francisco López-Muñoz; Winston W Shen; Chi-Un Pae; Raquel Moreno; Gabriel Rubio; Juan D Molina; Concha Noriega; Miguel A Pérez-Nieto; Lorena Huelves; Cecilio Alamo
Journal:  Psychiatry Investig       Date:  2013-02-08       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.